How big is PAVmed, Inc.?

As of Jun 18, PAVmed, Inc. has a market capitalization of 10.58 million and reported net sales of 2.00 million with a consolidated net profit of 65.56 million. The balance sheet shows shareholder's funds of -2.50 million and total assets of 30.66 million.

As of Jun 18, PAVmed, Inc. has a market capitalization of 10.58 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 2.00 million for the latest four quarters, alongside a consolidated net profit of 65.56 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of -2.50 million and total assets amounting to 30.66 million.

What does PAVmed, Inc. do?

PAVmed, Inc. is a micro-cap medical device company focused on developing and commercializing a diverse range of products in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $0 million and a net profit of $19 million, with a market cap of $10.58 million.

Overview:<BR>PAVmed, Inc. is a medical device company focused on conceiving, developing, and commercializing a diversified pipeline of products within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 19 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 10.58 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 0.00 <BR>Debt Equity: 0.09 <BR>Return on Equity: 92.94% <BR>Price to Book: 0.23 <BR><BR>Contact Details:<BR>Address: 1 Grand Central Terminal Ste 4600, NEW YORK NY: 10017-5743 <BR>Tel: ['1 212 9494319', '1 814 2414138'] <BR>Fax: 1 302 6555049 <BR>Website: http://www.pavm.com/

Should I buy, sell or hold PAVmed, Inc.?

Who are in the management team of PAVmed, Inc.?

As of March 2022, PAVmed, Inc.'s management team includes Lishan Aklog as Chairman and CEO, and Michael Glennon as Independent Vice Chairman, along with independent directors Dr. David Battleman, Dr. James Cox, Mr. Ronald Sparks, and Mr. David Weild.

As of March 2022, the management team of PAVmed, Inc. includes Mr. Lishan Aklog, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, Mr. Michael Glennon holds the position of Independent Vice Chairman of the Board. The Board of Directors also features several independent directors: Dr. David Battleman, Dr. James Cox, Mr. Ronald Sparks, and Mr. David Weild.

Is PAVmed, Inc. technically bullish or bearish?

As of September 2, 2025, PAVmed, Inc. shows a mildly bearish trend with mixed indicators, having underperformed the S&P 500 by -74.41% over the past year.

As of 2 September 2025, the technical trend for PAVmed, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish signal. The Bollinger Bands indicate a mildly bearish trend on the weekly chart and bearish on the monthly. Daily moving averages are bearish, and the KST is bearish weekly but mildly bullish monthly. The Dow Theory suggests a mildly bearish stance on the weekly timeframe with no trend monthly. Despite some mildly bullish signals from the OBV on both weekly and monthly charts, the overall technical picture remains weak.<BR><BR>Over the past year, PAVmed has significantly underperformed the S&P 500, with a return of -74.41% compared to the S&P's 17.14%.

Is PAVmed, Inc. overvalued or undervalued?

As of October 24, 2025, PAVmed, Inc. is considered overvalued with a fair valuation grade, reflected by key ratios indicating profitability challenges and a significant year-to-date stock underperformance of -34.92% compared to the S&P 500's 15.47%.

As of 24 October 2025, PAVmed, Inc. has moved from an attractive to a fair valuation grade. The company appears to be overvalued based on its current metrics. Key ratios include a Price to Book Value of 0.23, an EV to EBIT of -0.43, and an EV to EBITDA of -0.44, which suggest significant challenges in profitability and valuation relative to its assets.<BR><BR>In comparison to peers, PAVmed's P/E ratio stands at 0, while Delcath Systems, Inc. is considered expensive with a P/E of 68.06, and Neuronetics, Inc. is risky with a P/E of -5.11. The stark contrast in valuations highlights PAVmed's relative overvaluation in the current market context. Additionally, PAVmed's stock has underperformed significantly against the S&P 500, with a year-to-date return of -34.92% compared to the index's 15.47%, reinforcing concerns about its valuation.